OncoMatch/Clinical Trials/NCT06673693
Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
Is NCT06673693 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tislelizumab for head and neck squamous cell carcinoma (hnscc).
Treatment: Tislelizumab — Exploring the efficacy and safety of Tislelizumab combined with stereotactic body radiation therapy (SBRT) as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (HNSCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage III, IVA, IVB
Prior therapy
Cannot have received: surgery
Exception: diagnostic biopsies of primary and regional lymph nodes
Patients previously treated with head and neck surgery were excluded from diagnostic biopsies of primary and regional lymph nodes
Cannot have received: chemotherapy
Previous chemotherapy for any reason
Cannot have received: radiation therapy
radiotherapy in the head and neck area
Cannot have received: molecular targeted drug therapy
molecular targeted drug therapy
Cannot have received: anti-PD-1 therapy
anti-PD-1, anti-PD-L1, anti-PD-L2 and other drugs or drugs acting on another irritating or co-inhibitory T cell receptor (such as CTLA-4, OX 40, CD137) treatment
Cannot have received: cell biotherapy
cell biotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify